Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab

Abstract

MSI-H tumor status was found in only two of 82 (2.4%) Japanese patients with advanced HCC, one of whom had a complete response to pembrolizumab. Thus, MSI status should be assessed in patients with HCC who progress after standard of care treatment.